CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
ConditionSolid Tumor
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking University Cancer Hospital & Institute
About this trial
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Aged >18 years old; ECOG 0 or 1;
2. Patients with solid tumors;
3. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
4. life expectancy >=12 weeks.
Disqualifiers
1. Significant hepatic or renal dysfunction;
2. Is pregnant or ready to pregnant;
3. Cannot keep their states for half an hour;
4. Refusal to join the clinical study;
Trial design
Design model
Single group
Treatments tested in this trial
18F-FDG
DrugAll study participants will undergo one 18F-FDG PET/CT scan.
Treatment groups
15 Participants
are divided into 1 treatment groupGroup A: 68Ga-ACN376Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Standardized uptake value（SUV）
SUV is a semi-quantitative analysis index to describe the radioactive uptake of lesions, which has certain reference value for differentiating benign and malignant lesions。 The uptake of the tracer （68Ga-ACN376） in solid tumor lesions by measuring SUV on PET/CT.
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov